Investigating potential disparities in clinical trial eligibility and enrollment at an NCI-designated comprehensive cancer center

被引:0
|
作者
Patel, Monica A. A. [1 ]
Shah, Jennifer L. L. [2 ,7 ]
Brinley IV, Floyd John [3 ]
Abrahamse, Paul H. H. [4 ]
Veenstra, Christine M. M. [5 ,6 ]
Schott, Anne F. F. [5 ]
机构
[1] Univ Wisconsin, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI 53706 USA
[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI USA
[3] Biotechne ProteinSimple Inc, San Jose, CA USA
[4] Univ Michigan, Dept Biostat, Ann Arbor, MI USA
[5] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI USA
[6] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI USA
[7] Univ Michigan Med, Radiat Oncol, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA
来源
CANCER MEDICINE | 2023年 / 12卷 / 11期
关键词
clinical trials; disparities; patient eligibility; trial enrollment; PARTICIPATION; BARRIERS; WOMEN; RACE;
D O I
10.1002/cam4.5933
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although barriers to trial accrual are well-reported, few studies have explored trial eligibility and trial offers as potential drivers of disparities in cancer clinical trial enrollment.Methods: We identified patients with gastrointestinal (GI) or head/neck (HN) malignancies who were seen as new patients at the University of Michigan Health Rogel Cancer Center in 2016. By exhaustive review of the electronic medical record, we assessed the primary outcomes: (1) eligibility for, (2) documented offer of, and (3) enrollment in a clinical trial. All 41 of the clinical trials available to these patients were considered. Independent variables included clinical and non-clinical patient-related factors. We assessed associations between these variables and the primary outcomes using multivariable regression.Results: Of 1446 patients, 43% were female, 15% were over age 75, 6% were Black. 305 (21%) patients were eligible for a clinical trial. Among eligible patients, 154 (50%) had documentation of a trial offer and 90 (30%) enrolled. Among the GI cohort, bivariate analyses demonstrated that older age was associated with decreased trial eligibility. Bivariate analyses also demonstrated that Black race was associated with increased trial offer. After adjustment, patients 75 or older were less likely to be eligible for a clinical trial in the GI cohort; however, we found no significant associations between race and any of the outcomes after adjustment. Among eligible GI patients, we found no significant associations between non-clinical factors and enrollment. Among the HN cohort, bivariate analyses demonstrated that female sex, older age, Black race, and unpartnered marital status were associated with decreased likelihood of trial offer; however, we found no significant associations between race, age, and marital status and any of the outcomes after adjustment. We found no significant associations between non-clinical factors and eligibility after adjustment; however, women were less likely to be offered and to enroll in a clinical trial in the HN cohort.Conclusion: Factors associated with eligibility, documented offer, and enrollment differed between disease site cohorts at our institution. Future work is needed to ensure the equitable inclusion of women and elderly patients in clinical trials.
引用
收藏
页码:12802 / 12812
页数:11
相关论文
共 50 条
  • [31] Getting real about NCI-designated Cancer Center advertising
    Rubenson, David
    Kapp, Daniel S.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (04) : 195 - 196
  • [32] Assessment of readability of gynecologic cancer clinical trials literature at NCI-designated comprehensive cancer centers
    Chalif, Julia
    Khadroui, Wafa
    Vargas, Roberto
    O'Malley, David
    Chambers, Laura
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S110 - S111
  • [33] Is fertility preservation a part of comprehensive cancer care in the USA? A study of NCI-designated cancer center websites
    Adriana N. Vest
    Nelson T. Kuete
    Akanksha Mehta
    Journal of Cancer Survivorship, 2021, 15 : 906 - 911
  • [34] Is fertility preservation a part of comprehensive cancer care in the USA? A study of NCI-designated cancer center websites
    Vest, Adriana N.
    Kuete, Nelson T.
    Mehta, Akanksha
    JOURNAL OF CANCER SURVIVORSHIP, 2021, 15 (06) : 906 - 911
  • [35] Molecular Profiling and Clinical Outcomes in Malignant Melanoma: Experience at a NCI-Designated Cancer Center
    Zih, F. S.
    Kulkarni, N.
    Escalante, D. A.
    Meade, C.
    Osevala, N.
    Zibel-Man, M.
    Movva, S.
    Gustafson, K. S.
    Wu, H.
    Reddy, S.
    Lango, M.
    Olszanski, A. J.
    Farma, J.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S119 - S119
  • [36] Rapidly adapting the clinical research environment at an NCI-designated comprehensive cancer center to the COVID-19 pandemic.
    Lassman, Andrew B.
    Brogan, Frances L.
    Shelton, Ryan J.
    Bentlyewski, Edward
    Kelsen, Moshe A.
    Kim, Helen
    Ruotolo, Brenda L.
    Rustgi, Anil K.
    Jurcic, Joseph G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital
    Stacy D. Sanford
    Jennifer L. Beaumont
    Mallory A. Snyder
    Jennifer Reichek
    John M. Salsman
    Supportive Care in Cancer, 2017, 25 : 1579 - 1586
  • [38] Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital
    Sanford, Stacy D.
    Beaumont, Jennifer L.
    Snyder, Mallory A.
    Reichek, Jennifer
    Salsman, John M.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (05) : 1579 - 1586
  • [39] Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility
    Kurtzman, Rachel T.
    Mikesell, Lisa
    Crabtree, Benjamin F.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (07): : 475 - 481
  • [40] The status of oncofertility resources at NCI-designated comprehensive cancer centers.
    Clayman, M. L.
    Harper, M.
    Quinn, G. P.
    Shah, S.
    Reinecke, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)